vimarsana.com

Latest Breaking News On - Oculis sa - Page 1 : vimarsana.com

Oculis Announces Pricing of $40.25 Million Public Offering

ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to.

Boston
Massachusetts
United-states
China
Charlotte
North-carolina
France
Switzerland
Wedbush-pacgrow
David-daley
Tracy-cheung
Corey-davis

Press Release: Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development

Press Release: Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development Oculis Strengthens its Scientific Advisory Board with World-Leading

Stanford
California
United-states
Hebron
Israel-general
Israel
Paris
France-general
France
Tel-aviv
Stanford-university
China

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

China
Germany
Sweden
Denmark
Switzerland
Berlin
Swedish
Sensiparr-mimpara
Oculis-sa
Bastian-dehmel
Amgen
Glaxosmithkline

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

China
Germany
Sweden
Denmark
Switzerland
Berlin
Swedish
Brigid-lee
Amber-fennell
Nic-johnson
Louie-anne-gauthier
Sylvia-cheung


acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

China
Germany
Sweden
Denmark
Switzerland
Berlin
Swedish
Sensiparr-mimpara
Oculis-sa
Bastian-dehmel
Amgen
Glaxosmithkline
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.